Physician profile
Abigail Shaw
NPI 1770213670
$7,397.50
in general payments reported to CMS, 2019-2025
22 companies · $1,538 in 2025
The $1,538 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,095 · 2023: $2,454 · 2024: $2,310 · 2025: $1,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,107 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,107.09 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $1,357.31 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $1,082.56 | 2023-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $606.41 | 2022-2025 | Winlevi, Absorica Ld |
| Abbvie INC. | $591.33 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $529.56 | 2022-2025 | Sotyktu |
| Journey Medical Corporation | $451.21 | 2022-2023 | |
| Leo Pharma INC. | $360.88 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $303.13 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $272.21 | 2022-2023 | |
| Genzyme Corporation | $269.86 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $250.77 | 2022-2025 | |
| Incyte Corporation | $209.96 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $191.82 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $173.31 | 2023-2025 | Otezla, Otezla, Enbrel |
| Botanix Sb INC | $166.94 | 2025 | Sofdra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $123.28 | 2022-2025 | Oracea, Aklief, Twyneo |
| Mayne Pharma Commercial LLC | $118.28 | 2022-2023 | |
| Arcutis Biotherapeutics, INC. | $99.32 | 2023-2025 | Zoryve |
| Almirall LLC | $75.42 | 2022-2025 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $67.67 | 2023-2025 | Jublia, Cabtreo, Arazlo |
| Regeneron Healthcare Solutions, INC. | $66.13 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.14 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.